Technical Analysis for PMCB - PharmaCyte Biotech, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Stochastic Reached Oversold | Weakness | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Gapped Up | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
20 DMA Resistance | Bearish | 0.01% | |
50 DMA Resistance | Bearish | 0.01% | |
180 Bearish Setup | Bearish Swing Setup | 0.01% | |
Expansion Pivot Sell Setup | Bearish Swing Setup | 0.01% | |
Outside Day | Range Expansion | 0.01% | |
20 DMA Resistance | Bearish | -5.76% |
Alert | Time |
---|---|
Rose Above Previous Day's High | 3 days ago |
20 DMA Resistance | 3 days ago |
10 DMA Resistance | 3 days ago |
Down 1% | 3 days ago |
Up 1% | 3 days ago |
Get this analysis on your stocks daily!
- Earnings date: 07/29/2024
PharmaCyte Biotech, Inc. Description
PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the activation of cancer-killing drugs to the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. PharmaCyte Biotech, Inc. has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and a research agreement with the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Diabetes Pancreatic Cancer Therapies For Cancer Gastrointestinal Cancer Cell Encapsulation Geron Corporation Type 1 Diabetes
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.91 |
52 Week Low | 1.76 |
Average Volume | 20,387 |
200-Day Moving Average | 2.17 |
50-Day Moving Average | 2.10 |
20-Day Moving Average | 2.09 |
10-Day Moving Average | 2.05 |
Average True Range | 0.14 |
RSI (14) | 41.86 |
ADX | 13.47 |
+DI | 16.31 |
-DI | 15.64 |
Chandelier Exit (Long, 3 ATRs) | 1.98 |
Chandelier Exit (Short, 3 ATRs) | 2.31 |
Upper Bollinger Bands | 2.30 |
Lower Bollinger Band | 1.88 |
Percent B (%b) | 0.2 |
BandWidth | 20.21 |
MACD Line | -0.03 |
MACD Signal Line | -0.02 |
MACD Histogram | -0.0165 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.12 | ||||
Resistance 3 (R3) | 2.14 | 2.10 | 2.09 | ||
Resistance 2 (R2) | 2.10 | 2.06 | 2.09 | 2.09 | |
Resistance 1 (R1) | 2.03 | 2.04 | 2.01 | 2.01 | 2.08 |
Pivot Point | 2.00 | 2.00 | 1.99 | 1.99 | 2.00 |
Support 1 (S1) | 1.92 | 1.95 | 1.91 | 1.91 | 1.84 |
Support 2 (S2) | 1.89 | 1.93 | 1.88 | 1.83 | |
Support 3 (S3) | 1.82 | 1.89 | 1.83 | ||
Support 4 (S4) | 1.80 |